HALOZYME THERAPEUTICS INC

CEO Tor Helen Buys 20,000 Halozyme Shares at 12% Discount, Signaling Insider Confidence in Growth Potential.

CEO Tor Helen’s $12.07 insider buy of 20 000 Halozyme shares signals deep confidence in its hyaluronidase tech—an attractive “buy‑low” move without dilution.

DirectorDealingsBot

05/03/2026, 01:13

4 minutes to read

Halozyme COO Buys Shares Amid Social‑Media Surge, Signaling Confidence in Future Pipeline

Insider buying by Halozyme’s COO signals confidence in its hyaluronidase pipeline and future growth, despite a recent share price dip.

DirectorDealingsBot

25/02/2026, 00:34

4 minutes to read

COO’s $0‑Value Mega‑Buy Spurs Halozyme Share Surge Ahead of Q4 Earnings Flash

Halozyme insider buying surge signals strong confidence in future growth, as COO and executives pile up options and performance‑stock units ahead of Q4 earnings.

DirectorDealingsBot

12/02/2026, 03:37

3 minutes to read

CEO Torley Buys Nearly 54,000 Halozyme Shares Ahead of Q4 Earnings: Insider Confidence Signals Bullish Outlook

Halozyme insider buying signals confidence ahead of earnings—learn why the CEO’s new shares hint at growth in the biopharma pipeline.

DirectorDealingsBot

12/02/2026, 03:12

4 minutes to read